-
1
-
-
0037260139
-
Cancer statistics, 2003
-
Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
-
(2003)
CA Cancer J Clin
, vol.53
, pp. 5-26
-
-
Jemal, A.1
Murray, T.2
Samuels, A.3
-
2
-
-
0032497522
-
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
-
Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998
-
(1998)
N Engl J Med
, vol.339
, pp. 1036-1042
-
-
Eisenberger, M.A.1
Blumenstein, B.A.2
Crawford, E.D.3
-
3
-
-
0032784113
-
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
-
Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506-2513, 1999
-
(1999)
J Clin Oncol
, vol.17
, pp. 2506-2513
-
-
Kantoff, P.W.1
Halabi, S.2
Conaway, M.3
-
4
-
-
8944220720
-
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
-
Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 1756-1764
-
-
Tannock, I.F.1
Osoba, D.2
Stockler, M.R.3
-
5
-
-
0025882306
-
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
-
Warrell RP Jr, Frankel SR, Miller WH Jr, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385-1393, 1991
-
(1991)
N Engl J Med
, vol.324
, pp. 1385-1393
-
-
Warrell R.P., Jr.1
Frankel, S.R.2
Miller W.H., Jr.3
-
6
-
-
0025201879
-
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results
-
Castaigne S, Chomienne C, Daniel MT, et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 76:1704-1709, 1990
-
(1990)
Blood
, vol.76
, pp. 1704-1709
-
-
Castaigne, S.1
Chomienne, C.2
Daniel, M.T.3
-
7
-
-
0026040363
-
A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
-
Chen ZX, Xue YQ, Zhang R, et al: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413-1419, 1991
-
(1991)
Blood
, vol.78
, pp. 1413-1419
-
-
Chen, Z.X.1
Xue, Y.Q.2
Zhang, R.3
-
9
-
-
0035342671
-
The role of vitamin D in prostate cancer
-
Zhao XY, Feldman D: The role of vitamin D in prostate cancer. Steroids 66:293-300, 2001
-
(2001)
Steroids
, vol.66
, pp. 293-300
-
-
Zhao, X.Y.1
Feldman, D.2
-
10
-
-
0025187312
-
Is vitamin D deficiency a risk factor for prostate cancer?
-
Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10: 1307-1311, 1990
-
(1990)
Anticancer Res
, vol.10
, pp. 1307-1311
-
-
Schwartz, G.G.1
Hulka, B.S.2
-
12
-
-
0029160549
-
Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men
-
Corder EH, Friedman GD, Vogelman JH, et al: Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: Risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 4:655-659, 1995
-
(1995)
Cancer Epidemiol Biomarkers Prev
, vol.4
, pp. 655-659
-
-
Corder, E.H.1
Friedman, G.D.2
Vogelman, J.H.3
-
13
-
-
0033785622
-
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels
-
Ahonen MH, Tenkanen L, Teppo L, et al: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11:847-852, 2000
-
(2000)
Cancer Causes Control
, vol.11
, pp. 847-852
-
-
Ahonen, M.H.1
Tenkanen, L.2
Teppo, L.3
-
14
-
-
0029014444
-
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
-
Braun MM, Helzlsouer KJ, Hollis BW, et al: Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6:235-239, 1995
-
(1995)
Cancer Causes Control
, vol.6
, pp. 235-239
-
-
Braun, M.M.1
Helzlsouer, K.J.2
Hollis, B.W.3
-
15
-
-
0031719143
-
Serum vitamin D metabolite levels and the subsequent development of prostate cancer
-
Nomura AM, Stemmermann GN, Lee J, et al: Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9:425-432, 1998
-
(1998)
Cancer Causes Control
, vol.9
, pp. 425-432
-
-
Nomura, A.M.1
Stemmermann, G.N.2
Lee, J.3
-
16
-
-
33846319260
-
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
-
Gann PH, Ma J, Hennekens CH, et al: Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5:121-126, 1996
-
(1996)
Cancer Epidemiol Biomarkers Prev
, vol.5
, pp. 121-126
-
-
Gann, P.H.1
Ma, J.2
Hennekens, C.H.3
-
18
-
-
0029914170
-
The role of vitamin D in normal prostate growth and differentiation
-
Konety BR, Schwartz GG, Acierno JS Jr, et al: The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 7:1563-1570, 1996
-
(1996)
Cell Growth Differ
, vol.7
, pp. 1563-1570
-
-
Konety, B.R.1
Schwartz, G.G.2
Acierno J.S., Jr.3
-
24
-
-
0028168202
-
Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
-
Schwartz GG, Oeler TA, Uskokovic MR, et al: Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1081, 1994
-
(1994)
Anticancer Res
, vol.14
, pp. 1077-1081
-
-
Schwartz, G.G.1
Oeler, T.A.2
Uskokovic, M.R.3
-
26
-
-
0031463720
-
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
-
Getzenberg RH, Light BW, Lapco PE, et al: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50:999-1006, 1997
-
(1997)
Urology
, vol.50
, pp. 999-1006
-
-
Getzenberg, R.H.1
Light, B.W.2
Lapco, P.E.3
-
27
-
-
0032963132
-
Inhibition of prostate cancer metastasis in vivo: A comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089
-
Lokeshwar BL, Schwartz GG, Selzer MG, et al: Inhibition of prostate cancer metastasis in vivo: A comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8:241-248, 1999
-
(1999)
Cancer Epidemiol Biomarkers Prev
, vol.8
, pp. 241-248
-
-
Lokeshwar, B.L.1
Schwartz, G.G.2
Selzer, M.G.3
-
29
-
-
0036379695
-
3 and two synthetic analogues in three in vivo models of prostate cancer
-
3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 90:607-616, 2002
-
(2002)
BJU Int
, vol.90
, pp. 607-616
-
-
Oades, G.M.1
Dredge, K.2
Kirby, R.S.3
-
30
-
-
0032937372
-
3 and 9-cis retinoic acid in LNCaP human prostate cancer cells
-
3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205-1212, 1999
-
(1999)
Endocrinology
, vol.140
, pp. 1205-1212
-
-
Zhao, X.Y.1
Ly, L.H.2
Peehl, D.M.3
-
31
-
-
85047683799
-
3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms
-
3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141:2548-2556, 2000
-
(2000)
Endocrinology
, vol.141
, pp. 2548-2556
-
-
Zhao, X.Y.1
Peehl, D.M.2
Navone, N.M.3
-
32
-
-
0034463114
-
Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2
-
Blutt SE, McDonnell TJ, Polek TC, et al: Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17, 2000
-
(2000)
Endocrinology
, vol.141
, pp. 10-17
-
-
Blutt, S.E.1
McDonnell, T.J.2
Polek, T.C.3
-
33
-
-
0030910440
-
3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1
-
3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138: 1491-1497, 1997
-
(1997)
Endocrinology
, vol.138
, pp. 1491-1497
-
-
Blutt, S.E.1
Allegretto, E.A.2
Pike, J.W.3
-
34
-
-
85047680777
-
3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
-
3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998
-
(1998)
Endocrinology
, vol.139
, pp. 1197-1207
-
-
Zhuang, S.H.1
Burnstein, K.L.2
-
38
-
-
0030809595
-
1 Alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
-
Schwartz GG, Wang MH, Zang M, et al: 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727-732, 1997
-
(1997)
Cancer Epidemiol Biomarkers Prev
, vol.6
, pp. 727-732
-
-
Schwartz, G.G.1
Wang, M.H.2
Zang, M.3
-
39
-
-
0034691008
-
3 decreases human prostate cancer cell adhesion and migration
-
3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164:133-143, 2000
-
(2000)
Mol Cell Endocrinol
, vol.164
, pp. 133-143
-
-
Sung, V.1
Feldman, D.2
-
40
-
-
85047685002
-
Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells
-
Bernardi RJ, Johnson CS, Modzelewski RA, et al: Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508-2514, 2002
-
(2002)
Endocrinology
, vol.143
, pp. 2508-2514
-
-
Bernardi, R.J.1
Johnson, C.S.2
Modzelewski, R.A.3
-
41
-
-
8844273350
-
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression
-
Krishnan AV, Peehl DM, Feldman D: Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88:363-371, 2003
-
(2003)
J Cell Biochem
, vol.88
, pp. 363-371
-
-
Krishnan, A.V.1
Peehl, D.M.2
Feldman, D.3
-
42
-
-
0032978243
-
A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy
-
Smith DC, Johnson CS, Freeman CC, et al: A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5:1339-1345, 1999
-
(1999)
Clin Cancer Res
, vol.5
, pp. 1339-1345
-
-
Smith, D.C.1
Johnson, C.S.2
Freeman, C.C.3
-
43
-
-
0036716825
-
Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer
-
Liu G, Oettel K, Ripple G, et al: Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 8:2820-2827, 2002
-
(2002)
Clin Cancer Res
, vol.8
, pp. 2820-2827
-
-
Liu, G.1
Oettel, K.2
Ripple, G.3
-
44
-
-
0035875881
-
A Phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation
-
Beer TM, Munar M, Henner WD: A Phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation. Cancer 91:2431-2439, 2001
-
(2001)
Cancer
, vol.91
, pp. 2431-2439
-
-
Beer, T.M.1
Munar, M.2
Henner, W.D.3
-
45
-
-
0001013226
-
Phase II trial of oral 1,25 dihydroxyvitamin D (calcitriol) in hormone-refractory prostate cancer
-
Osborn JL, Schwartz GG, Smith DC, et al: Phase II trial of oral 1,25 dihydroxyvitamin D (calcitriol) in hormone-refractory prostate cancer. Urol Oncol 1:195-198, 1995
-
(1995)
Urol Oncol
, vol.1
, pp. 195-198
-
-
Osborn, J.L.1
Schwartz, G.G.2
Smith, D.C.3
-
47
-
-
0037372282
-
High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma
-
Beer TM, Lemmon D, Lowe BA, et al: High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97:1217-1224, 2003
-
(2003)
Cancer
, vol.97
, pp. 1217-1224
-
-
Beer, T.M.1
Lemmon, D.2
Lowe, B.A.3
-
48
-
-
0037208558
-
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer
-
Beer TM, Eilers KM, Garzotto M, et al: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123-128, 2003
-
(2003)
J Clin Oncol
, vol.21
, pp. 123-128
-
-
Beer, T.M.1
Eilers, K.M.2
Garzotto, M.3
-
49
-
-
0036075032
-
Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model
-
Ahmed S, Johnson CS, Rueger RM, et al: Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 168:756-761, 2002
-
(2002)
J Urol
, vol.168
, pp. 756-761
-
-
Ahmed, S.1
Johnson, C.S.2
Rueger, R.M.3
-
50
-
-
0034908713
-
Rationale for combination ketoconazole/vitamin D treatment of prostate cancer
-
Peehl DM, Seto E, Feldman D: Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. Urology 58:123-126, 2001
-
(2001)
Urology
, vol.58
, pp. 123-126
-
-
Peehl, D.M.1
Seto, E.2
Feldman, D.3
-
53
-
-
0034943192
-
Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells
-
Nwankwo JO, Robbins ME: Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot Essent Fatty Acids 64:241-245, 2001
-
(2001)
Prostaglandins Leukot Essent Fatty Acids
, vol.64
, pp. 241-245
-
-
Nwankwo, J.O.1
Robbins, M.E.2
-
54
-
-
0036286540
-
Peroxisome proliferator-activated receptor gamma (PPARgamma) as a novel target for prostate cancer
-
Smith MR, Kantoff PW: Peroxisome proliferator-activated receptor gamma (PPARgamma) as a novel target for prostate cancer. Invest New Drugs 20:195-200, 2002
-
(2002)
Invest New Drugs
, vol.20
, pp. 195-200
-
-
Smith, M.R.1
Kantoff, P.W.2
-
55
-
-
0033616795
-
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma
-
Demetri GD, Fletcher CD, Mueller E, et al: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96:3951-3956, 1999
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 3951-3956
-
-
Demetri, G.D.1
Fletcher, C.D.2
Mueller, E.3
-
56
-
-
12644265334
-
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
-
Tontonoz P, Singer S, Forman BM, et al: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94:237-241, 1997
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 237-241
-
-
Tontonoz, P.1
Singer, S.2
Forman, B.M.3
-
57
-
-
0032586875
-
Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells
-
Takahashi N, Okumura T, Motomura W, et al: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455:135-139, 1999
-
(1999)
FEBS Lett
, vol.455
, pp. 135-139
-
-
Takahashi, N.1
Okumura, T.2
Motomura, W.3
-
58
-
-
0033741281
-
Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists
-
Sato H, Ishihara S, Kawashima K, et al: Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 83:1394-1400, 2000
-
(2000)
Br J Cancer
, vol.83
, pp. 1394-1400
-
-
Sato, H.1
Ishihara, S.2
Kawashima, K.3
-
59
-
-
0035458324
-
PPARgamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis cell cycle arrest and reduction of ornithine decarboxylase activity
-
Takashima T, Fujiwara Y, Higuchi K, et al: PPARgamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 19:465-471, 2001
-
(2001)
Int J Oncol
, vol.19
, pp. 465-471
-
-
Takashima, T.1
Fujiwara, Y.2
Higuchi, K.3
-
60
-
-
0031671246
-
Differentiation and reversal of malignant changes in colon cancer through PPARgamma
-
Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052, 1998
-
(1998)
Nat Med
, vol.4
, pp. 1046-1052
-
-
Sarraf, P.1
Mueller, E.2
Jones, D.3
-
61
-
-
0031993322
-
Terminal differentiation of human breast cancer through PPAR gamma
-
Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1:465-470, 1998
-
(1998)
Mol Cell
, vol.1
, pp. 465-470
-
-
Mueller, E.1
Sarraf, P.2
Tontonoz, P.3
-
62
-
-
0035964872
-
Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists
-
Inoue K, Kawahito Y, Tsubouchi Y, et al: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287:727-732, 2001
-
(2001)
Biochem Biophys Res Commun
, vol.287
, pp. 727-732
-
-
Inoue, K.1
Kawahito, Y.2
Tsubouchi, Y.3
-
63
-
-
0036754728
-
Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists
-
Hase T, Yoshimura R, Mitsuhashi M, et al: Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 60:542-547, 2002
-
(2002)
Urology
, vol.60
, pp. 542-547
-
-
Hase, T.1
Yoshimura, R.2
Mitsuhashi, M.3
-
64
-
-
0033152206
-
Loss-of-function mutations in PPAR gamma associated with human colon cancer
-
Sarraf P, Mueller E, Smith WM, et al: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3:799-804, 1999
-
(1999)
Mol Cell
, vol.3
, pp. 799-804
-
-
Sarraf, P.1
Mueller, E.2
Smith, W.M.3
-
65
-
-
0036730017
-
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
-
Kulke MH, Demetri GD, Sharpless NE, et al: A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8:395-399, 2002
-
(2002)
Cancer J
, vol.8
, pp. 395-399
-
-
Kulke, M.H.1
Demetri, G.D.2
Sharpless, N.E.3
-
66
-
-
0036570532
-
Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer
-
Segawa Y, Yoshimura R, Hase T, et al: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51:108-116, 2002
-
(2002)
Prostate
, vol.51
, pp. 108-116
-
-
Segawa, Y.1
Yoshimura, R.2
Hase, T.3
-
67
-
-
0343855442
-
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer
-
Mueller E, Smith M, Sarraf P, et al: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97:10990-10995, 2000
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, pp. 10990-10995
-
-
Mueller, E.1
Smith, M.2
Sarraf, P.3
-
68
-
-
0032145363
-
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
-
Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352, 1998
-
(1998)
Cancer Res
, vol.58
, pp. 3344-3352
-
-
Kubota, T.1
Koshizuka, K.2
Williamson, E.A.3
-
69
-
-
0034306976
-
Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer
-
Hisatake JI, Ikezoe T, Carey M, et al: Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60:5494-5498, 2000
-
(2000)
Cancer Res
, vol.60
, pp. 5494-5498
-
-
Hisatake, J.I.1
Ikezoe, T.2
Carey, M.3
-
71
-
-
0142061276
-
Identification of PPAR gamma specific target genes in prostate cancer cells
-
abstr
-
Mueller E, Febbo P, Sarraf P, et al: Identification of PPAR gamma specific target genes in prostate cancer cells. Proc Am Assoc Cancer Res 44:605, 2003 (abstr)
-
(2003)
Proc Am Assoc Cancer Res
, vol.44
, pp. 605
-
-
Mueller, E.1
Febbo, P.2
Sarraf, P.3
|